Back in March, we never could have predicted the impacts of COVID-19 would last this long.
But it’s August now, and it’s still here.
It’s impossible to know for sure when things will turn around, and until then, we just have to wait.
One thing is certain, though…
We need to make sure that a global crisis of this magnitude never happens again.
And the only way forward is to develop a vaccine.
According to the New York Times, there are more than 165 vaccines in some stage of development around the world… and six of these vaccines have made it to Phase III trials.
The companies producing two of these vaccines are rolling out trials with around 30,000 healthy people each from around the world.
One has received nearly $1 billion in government funding to back their production efforts, and the other has signed over $1 billion in dosage contracts with the United States and Japan.
And another company has seen equally promising results, with Phase II and III vaccine trials taking place all across the world. This team has already received over $1 billion in production support.
This is all exciting news. Governments around the world are pouring billions of dollars into biotech research… and it sounds like their efforts are starting to shape up.
Because they know as well as we do that the only way to get back to our daily lives, to turn the economy around, and ultimately, to stop this deadly pandemic in its tracks is to push full speed ahead on vaccine development.
But let’s think about this from another perspective… as potential investors.
Even before COVID-19 was ever on our radars, the biotech industry had been making serious gains.
And for good reason, too.
It all boils down to one of my core angel investing philosophies… that there is money to be made in industries solving massive problems. And there aren’t many problems much bigger than the ones biotech is trying to solve.
The global biotech market is expected to reach $727 billion by just 2025, and I’m sure that any effort on the COVID-19 vaccine front will only add to that estimate.
Considering these numbers, the folks who get in on just the right vaccine opportunity have a chance at paydays rivaling anything they’ve ever seen before.
That’s why I’ve spent a lot of time researching up-and-coming vaccine solutions with serious potential… and I recently found one.
It’s a tiny company that could rocket in value very soon… I’m talking about a potential 58,000% revenue explosion by the end of the year alone.
Their vaccine has already generated an immune response in human trials, and it’s been granted Phase I approval by the FDA in record time.
In fact, this company is so confident in their product that they’ve signed a contract to produce one billion doses over the next year… and production is expected to begin within the coming days.
They have eventual plans to produce over 10 billion doses of this vaccine… an extremely impressive endeavor for such a small company.
Their viable vaccine has the potential to be one of the biggest game changers in the history of modern medicine, but you’ll have to move fast if you want to get in.
The profit potential here is enormous, and I really don’t want you to miss what could be one of the biggest and most impactful biotech opportunities you’ll ever see.
So just click here to get all the information, and I’ll be back soon with another update.
Until next time,
August 06 2020